U.S. markets closed
  • S&P 500

    4,455.48
    +6.50 (+0.15%)
     
  • Dow 30

    34,798.00
    +33.18 (+0.10%)
     
  • Nasdaq

    15,047.70
    -4.54 (-0.03%)
     
  • Russell 2000

    2,248.07
    -10.97 (-0.49%)
     
  • Crude Oil

    73.95
    +0.65 (+0.89%)
     
  • Gold

    1,750.60
    +0.80 (+0.05%)
     
  • Silver

    22.42
    -0.26 (-1.16%)
     
  • EUR/USD

    1.1718
    -0.0029 (-0.25%)
     
  • 10-Yr Bond

    1.4600
    +0.0500 (+3.55%)
     
  • GBP/USD

    1.3681
    -0.0040 (-0.29%)
     
  • USD/JPY

    110.6850
    +0.3840 (+0.35%)
     
  • BTC-USD

    42,760.28
    -108.02 (-0.25%)
     
  • CMC Crypto 200

    1,067.20
    -35.86 (-3.25%)
     
  • FTSE 100

    7,051.48
    -26.87 (-0.38%)
     
  • Nikkei 225

    30,248.81
    +609.41 (+2.06%)
     

Iveric Bio Reveals Positive Post-Hoc Analyses Of Zimura In Dry Age-Related Macular Degeneration

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Iveric Bio Inc (NASDAQ: ISEE) has shared the new post-hoc analyses of GATHER1 and the progress of GATHER2 clinical trials evaluating Zimura (avacincaptad pegol) for geographic atrophy (G.A.) secondary to age-related macular degeneration (AMD).

  • GATHER1 18 month post-hoc analyses show that Zimura 2 mg can potentially impact earlier stages of dry AMD before G.A.

  • A 19.6% reduction in the rate of progression from drusen to nascent G.A. (iRORA/cRORA) compared to sham was observed, representing a relative risk reduction of 72%.

  • iRORA/cRORA are earlier forms of dry AMD.

  • A 21.8% reduction in the rate of progression from iRORA to cRORA compared to sham, equivalent to 52% risk reduction.

  • The company will discuss an accelerated enrollment timeline and patient retention, including injection fidelity, for GATHER2.

  • It expects to complete enrollment in late July.

  • Topline data from GATHER2 is expected in the 2H of 2022.

  • ISEE will hold a webcast today at 10:00 a.m. E.T.

  • Price Action: ISEE shares are up 6.12% at $6.24 in the premarket session on the last check Friday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.